Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) EBT (2016 - 2025)

Historic EBT for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $7.6 million.

  • Gyre Therapeutics' EBT rose 9412.21% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 11962.43%. This contributed to the annual value of $23.2 million for FY2024, which is 13016.7% up from last year.
  • Latest data reveals that Gyre Therapeutics reported EBT of $7.6 million as of Q3 2025, which was up 9412.21% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' EBT ranged from a high of $51.6 million in Q2 2022 and a low of -$100.3 million during Q4 2023
  • Its 5-year average for EBT is -$6.2 million, with a median of $2.2 million in 2025.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 45319.52% in 2021, then surged by 35909.27% in 2022.
  • Gyre Therapeutics' EBT (Quarter) stood at -$20.3 million in 2021, then fell by 12.27% to -$22.8 million in 2022, then plummeted by 339.82% to -$100.3 million in 2023, then soared by 100.77% to $772000.0 in 2024, then skyrocketed by 888.21% to $7.6 million in 2025.
  • Its last three reported values are $7.6 million in Q3 2025, $2.2 million for Q2 2025, and $4.6 million during Q1 2025.